Clinical Trial Search

Primary: Evaluation of Maximum Pain Intensity Change Over 24 Hours With the Addition of IV Acetaminophen and IV Ibuprofen — 6.48; 7.27; 6.16; 5.30 units on a scale

Primary: Number of Infants With Recurrent Wheezing — 42; 56 Participants — p=0.02

Primary: Number of Participants With Sustained Headache Relief Assessed by Self-evaluation — 40; 38 Participants

Primary: Mean Number of Intravitreal Aflibercept Injections for Subjects Who Were Enrolled and Completed the 3-year VISTA DME (VGFT-OD-1009) Trial — 9.5 injections

Primary: Percentage of Participants With a ≥ 50% Decrease From Baseline in the Frequency of Headache Days — 40.0; 12.0 percentage of participants — p=<0.001

Primary: Percentage of Participants Who Prefer the Once-monthly Dosing of Ibandronate to the Once-weekly Dosing of Risedronate — 62.42; 21.02 Percentage of participants — p=<0.0001

Primary: ADHD-RS Total Score — 39.58; 39.75; 20.03; 17.59 units on a scale

Primary: The Go/No-Go Task Percentage Assessed by fMRI — 91.7; 97.0; 88.7; 87.9 percentage correct responses/inhibitions

Primary: Patient Survival — 109; 104 Participants

Primary: Number of Participants With Sustained Headache Relief Assessed by Self-evaluation — 20; 37 Participants

Primary: Percent Heavy Drinking Days by mu Opioid Receptor Gene — 11.0; 18.0; 11.8; 18.7 percentage of days — p=0.724

Primary: Headache Pain Level on a 0-10 Verbal Scale — 4.7; 3.9; 2.8 units on a scale

Primary: Number of Participants With Wound Complications (Surgical Site Infection (SSI), Hematoma, Separation, Seroma, Etc) — 23; 37; 16; 25 Participants — p=0.04

Primary: Blood Pressure Change During Salt Loading — -25.5; 34.6; 23.2; -41.4 mmHg — p=>0.05

Primary: Increase in Number of Expressed Genes in Muscle and Adipose Tissue Using RNA Sequencing (RNA-Seq) — 245; 402; 15; 132 genes